U.S. Markets open in 5 hrs 12 mins

(BLCM) Alert: Johnson Fistel, LLP Announces Investigation of Bellicum Pharmaceuticals, Inc.; Long Term Investors Encouraged to Contact Firm

SAN DIEGO, May 20, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by Bellicum Pharmaceuticals, Inc. (BLCM) ("Bellicum")  and certain of its officers.

Last year a securities class action lawsuit was filed on behalf of purchasers of the securities of Bellicum from May 8, 2017 and January 30, 2018, (the "Class Period"). According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) a substantial undisclosed risk of encephalopathy was associated with the Bellicum's lead product candidate, BPX-501; and (2) as a result, Bellicum's public statements were materially false and misleading at all relevant times.

If you are a long-term shareholder of Bellicum continuously holding shares before May 8, 2017, you may have standing to hold Bellicum harmless from the alleged harm caused by the officers and directors of the Company by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.

If you are interested in learning more about your legal rights and remedies, please contact Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If you email, please include your phone number.

Additionally, you can  [click here to join this action]. There is no cost or obligation to you.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com

[click here to join this action]

Cision

View original content:http://www.prnewswire.com/news-releases/blcm-alert-johnson-fistel-llp-announces-investigation-of-bellicum-pharmaceuticals-inc-long-term-investors-encouraged-to-contact-firm-300853100.html